An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

Chimerix

Status and phase: Withdrawn; Phase 2

Conditions: Ebola Virus

Treatments: Drug: CMX001

Study type: Interventional

Funder types: Industry

Identifiers

NCT02271347

CMX001-205

Details and patient eligibility

About

The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.

Sex: All

Ages: 2 months to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Positive for Ebola virus RNA in plasma
• Subject must be able to ingest, absorb, and tolerate oral medication
• Subject must be willing to use adequate contraception during their participation

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

CMX001

Experimental group

Description:

CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.

Treatment:

Drug: CMX001